These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 35163968)

  • 1. Identification of Novel Cannabinoid CB2 Receptor Agonists from Botanical Compounds and Preliminary Evaluation of Their Anti-Osteoporotic Effects.
    Hu SJ; Cheng G; Zhou H; Zhang Q; Zhang QL; Wang Y; Shen Y; Lian CX; Ma XQ; Zhang QY; Qin LP
    Molecules; 2022 Jan; 27(3):. PubMed ID: 35163968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective Cannabinoid 2 Receptor Agonists as Potential Therapeutic Drugs for the Treatment of Endotoxin-Induced Uveitis.
    Porter RF; Szczesniak AM; Toguri JT; Gebremeskel S; Johnston B; Lehmann C; Fingerle J; Rothenhäusler B; Perret C; Rogers-Evans M; Kimbara A; Nettekoven M; Guba W; Grether U; Ullmer C; Kelly MEM
    Molecules; 2019 Sep; 24(18):. PubMed ID: 31540271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ligand-based virtual screening identifies a family of selective cannabinoid receptor 2 agonists.
    Gianella-Borradori M; Christou I; Bataille CJ; Cross RL; Wynne GM; Greaves DR; Russell AJ
    Bioorg Med Chem; 2015 Jan; 23(1):241-63. PubMed ID: 25487422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Pyridone-Based Derivatives as Cannabinoid Receptor Type 2 Agonists.
    Faúndez-Parraguez M; Alarcón-Miranda C; Cho YH; Pessoa-Mahana H; Gallardo-Garrido C; Chung H; Faúndez M; Pessoa-Mahana D
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, in vitro and in vivo evaluation of 1,3,5-triazines as cannabinoid CB2 receptor agonists.
    Yrjölä S; Sarparanta M; Airaksinen AJ; Hytti M; Kauppinen A; Pasonen-Seppänen S; Adinolfi B; Nieri P; Manera C; Keinänen O; Poso A; Nevalainen TJ; Parkkari T
    Eur J Pharm Sci; 2015 Jan; 67():85-96. PubMed ID: 25447744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological potential of JWH133, a cannabinoid type 2 receptor agonist in neurodegenerative, neurodevelopmental and neuropsychiatric diseases.
    Hashiesh HM; Jha NK; Sharma C; Gupta PK; Jha SK; Patil CR; Goyal SN; Ojha SK
    Eur J Pharmacol; 2021 Oct; 909():174398. PubMed ID: 34332924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking.
    Ragusa G; Gómez-Cañas M; Morales P; Rodríguez-Cueto C; Pazos MR; Asproni B; Cichero E; Fossa P; Pinna GA; Jagerovic N; Fernández-Ruiz J; Murineddu G
    Eur J Med Chem; 2017 Feb; 127():398-412. PubMed ID: 28088085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
    Zagzoog A; Mohamed KA; Kim HJJ; Kim ED; Frank CS; Black T; Jadhav PD; Holbrook LA; Laprairie RB
    Sci Rep; 2020 Nov; 10(1):20405. PubMed ID: 33230154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of
    Intranuovo F; Brunetti L; DelRe P; Mangiatordi GF; Stefanachi A; Laghezza A; Niso M; Leonetti F; Loiodice F; Ligresti A; Kostrzewa M; Brea J; Loza MI; Sotelo E; Saviano M; Colabufo NA; Riganti C; Abate C; Contino M
    J Med Chem; 2023 Jan; 66(1):235-250. PubMed ID: 36542836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cannabinoid 2 receptor is a novel anti-inflammatory target in experimental proliferative vitreoretinopathy.
    Szczesniak AM; Porter RF; Toguri JT; Borowska-Fielding J; Gebremeskel S; Siwakoti A; Johnston B; Lehmann C; Kelly ME
    Neuropharmacology; 2017 Feb; 113(Pt B):627-638. PubMed ID: 27569993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneity of cannabinoid ligand-induced modulations in intracellular Ca
    Xia KK; Shen JX; Huang ZB; Song HM; Gao M; Chen DJ; Zhang SJ; Wu J
    Acta Pharmacol Sin; 2019 Mar; 40(3):410-417. PubMed ID: 30202013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Negative allosteric modulators of cannabinoid receptor 2: protein modeling, binding site identification and molecular dynamics simulations in the presence of an orthosteric agonist.
    Pandey P; Roy KK; Doerksen RJ
    J Biomol Struct Dyn; 2020 Jan; 38(1):32-47. PubMed ID: 30652534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patent review of cannabinoid receptor type 2 (CB
    Kosar M; Mach L; Carreira EM; Nazaré M; Pacher P; Grether U
    Expert Opin Ther Pat; 2024 Aug; 34(8):665-700. PubMed ID: 38886185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of select synthetic cannabinoid receptor agonist bias and selectivity between the type 1 and type 2 cannabinoid receptor.
    Zagzoog A; Brandt AL; Black T; Kim ED; Burkart R; Patel M; Jin Z; Nikolaeva M; Laprairie RB
    Sci Rep; 2021 May; 11(1):10611. PubMed ID: 34012003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabinoid CB
    Soethoudt M; Grether U; Fingerle J; Grim TW; Fezza F; de Petrocellis L; Ullmer C; Rothenhäusler B; Perret C; van Gils N; Finlay D; MacDonald C; Chicca A; Gens MD; Stuart J; de Vries H; Mastrangelo N; Xia L; Alachouzos G; Baggelaar MP; Martella A; Mock ED; Deng H; Heitman LH; Connor M; Di Marzo V; Gertsch J; Lichtman AH; Maccarrone M; Pacher P; Glass M; van der Stelt M
    Nat Commun; 2017 Jan; 8():13958. PubMed ID: 28045021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional CB2 type cannabinoid receptors at CNS synapses.
    Morgan NH; Stanford IM; Woodhall GL
    Neuropharmacology; 2009 Sep; 57(4):356-68. PubMed ID: 19616018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease.
    González-Naranjo P; Pérez-Macias N; Campillo NE; Pérez C; Arán VJ; Girón R; Sánchez-Robles E; Martín MI; Gómez-Cañas M; García-Arencibia M; Fernández-Ruiz J; Páez JA
    Eur J Med Chem; 2014 Feb; 73():56-72. PubMed ID: 24378710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CB2 cannabinoid receptor agonist enantiomers HU-433 and HU-308: An inverse relationship between binding affinity and biological potency.
    Smoum R; Baraghithy S; Chourasia M; Breuer A; Mussai N; Attar-Namdar M; Kogan NM; Raphael B; Bolognini D; Cascio MG; Marini P; Pertwee RG; Shurki A; Mechoulam R; Bab I
    Proc Natl Acad Sci U S A; 2015 Jul; 112(28):8774-9. PubMed ID: 26124120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of type 2 cannabinoid receptor (CB2R) by selective agonists regulates the deposition and remodelling of the extracellular matrix.
    Guan T; Zhao G; Duan H; Liu Y; Zhao F
    Biomed Pharmacother; 2017 Nov; 95():1704-1709. PubMed ID: 28958132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modern approaches to the development of synthetic cannabinoid receptor probes.
    Saldaña-Shumaker SL; Grenning AJ; Cunningham CW
    Pharmacol Biochem Behav; 2021 Apr; 203():173119. PubMed ID: 33508249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.